Login to Your Account

Struggling Sonus Building Value, Pipeline via OncoGenex Merger

By Jennifer Boggs

Thursday, May 29, 2008
Sonus Pharmaceuticals Inc., which has fought to rebuild shareholder value following the failure of lead drug Tocosol Paclitaxel in a pivotal Phase III trial in September, is bolstering its clinical pipeline with the acquisition of Canadian biotech OncoGenex Technologies Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription